Collaborations and License Agreements (Details)		1 Months Ended																3 Months Ended				6 Months Ended		12 Months Ended
	Aug. 01, 2019 USD ($)	Feb. 28, 2022 USD ($)	Aug. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Feb. 28, 2019 USD ($)	Nov. 30, 2018 USD ($)	Feb. 28, 2018 USD ($)	Oct. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Aug. 31, 2017 USD ($) milestone	Dec. 31, 2016	Dec. 31, 2015 USD ($)	Aug. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2006 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2022 USD ($) indication	Jun. 30, 2021 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2021 USD ($)	Apr. 30, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Trade receivables, net																		$ 15,279,000				$ 15,279,000			$ 9,811,000
Revenues																		25,304,000	$ 7,556,000			46,224,000	$ 9,476,000
EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement received								$ 2,000,000	$ 4,000,000			$ 2,500,000
Number of milestones | milestone										3
Collaborations and license agreements, expected milestone receivable					$ 2,000,000	$ 2,000,000	$ 2,000,000			$ 2,000,000
Percentage of EUSA cost-sharing for TIVO-3 trial																								50.00%
Milestone payments to be received																		2,000,000				2,000,000
Potential milestone payment to be received																		$ 2,000,000				2,000,000
Payments received in connection per indication																						$ 2,000,000
Eligible number of indications | indication																						3
Payments received in connection with additional indications																						$ 5,000,000
Potential payments received in connection with additional indications																						335,000,000
Research and development reimbursement milestone																						$ 20,000,000.0
Sublicense fee to earned milestone payments and royalties																		30.00%				30.00%
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements																		30.00%				30.00%
Milestone payment																		$ 8,700,000				$ 8,700,000
Milestone payment subject to sublicense fees																		20,000,000				20,000,000
Allocation of upfront payment					$ 600,000	$ 600,000	$ 600,000
Revenues																		300,000	800,000			1,100,000	1,700,000
KKC Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																		0				0
Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues				$ 25,000,000																$ 2,800,000
Milestone payment received			$ 2,800,000
Royalties on the net sales																		3,000,000	800,000			5,400,000	900,000
Non refundable upfront payment																					$ 25,000,000
Transaction price																				$ 27,800,000
Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment		$ 2,300,000
Term after first sale													10 years
Termination notice period													6 months
Maximum | Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments														$ 50,000,000
Maximum | Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognition milestone method milestone payables																		12,100,000				12,100,000
Collaboration and Licensing Revenue | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate transaction price												$ 12,500,000						12,500,000				12,500,000		$ 12,500,000
Revenues																		0	500,000			600,000	1,000,000
Partnership licensing and royalty revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																		298,000	821,000			1,132,000	1,675,000
Partnership licensing and royalty revenue | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																		300,000	300,000			500,000	700,000
Accounts receivable																		300,000				300,000
License | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																		0	0			0	0
Opt In To Planned Phase Three Study | Minimum | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eusa potential opt-In payment TIVO three trial																						8,700,000
Opt In To Planned Phase Three Study | Maximum | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement potential opt-in payment																						20,000,000.0
Astra Zeneca Agreement | Astra Zeneca Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																		200,000	$ 300,000			400,000	$ 500,000
Trade receivables, net																		400,000				400,000
FOCAL study | Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty on future product sales, percentage of future licensing revenue																										25.00%
Required payment amount for agreement																										$ 2,500,000
FOCAL study | Minimum | Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contribution percentage of clinical, regulatory, manufacturing and other costs																										50.00%
Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, one time milestone payment waived	$ 18,000,000.0
Collaborations and license agreements, expected milestone receivable																						390,700,000
Milestone payment received			$ 2,800,000
Term of royalty payment obligations			10 years
Non refundable upfront payment	25,000,000
Aggregate milestone payments																		$ 387,900,000				$ 387,900,000
Licensing Agreements | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received													$ 1,500,000
Licensing Agreements | KKC Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment receivable				$ 25,000,000
Collaborations and license agreements, one time milestone payment waived	$ 18,000,000
Upfront payment received																	$ 5,000,000
Collaborations and license agreements, milestone payment																$ 10,000,000
Licensing Agreements | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements																		30.00%				30.00%
Term of royalty payment obligations											12 years
Licensing Agreements | FDA Marketing Approval | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment															$ 12,000,000